These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10771678)

  • 1. [Histone deacetylase inhibitors--new anticancer agents?].
    Yoshida M; Horinouchi S
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biological diversity of protein lysine acetylation which has been revealed by small molecule inhibitors].
    Shimazu T; Horinouchi S; Yoshida M
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1751-7. PubMed ID: 18051411
    [No Abstract]   [Full Text] [Related]  

  • 3. [Epigenetics in hematological disorders].
    Furukawa Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
    [No Abstract]   [Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
    Richon VM; O'Brien JP
    Clin Cancer Res; 2002 Mar; 8(3):662-4. PubMed ID: 11895892
    [No Abstract]   [Full Text] [Related]  

  • 5. [A new target of cancer therapy: advances in the study of histone deacetylase].
    Liu AL; Long J; Wang N; Du GH
    Yao Xue Xue Bao; 2005 Jul; 40(7):585-90. PubMed ID: 16196262
    [No Abstract]   [Full Text] [Related]  

  • 6. [The complexes for histone acetyltransferase and histone deacetylase].
    Suka N
    Tanpakushitsu Kakusan Koso; 1999 Sep; 44(12 Suppl):1788-95. PubMed ID: 10503015
    [No Abstract]   [Full Text] [Related]  

  • 7. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 8. [Structure and function of chromatin centered on histone acetyltransferase and histone deacetylase].
    Horikoshi M
    Tanpakushitsu Kakusan Koso; 2000 Jun; 45(9 Suppl):1446-64. PubMed ID: 10879121
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibitors of histone deacetylase are potentially effective anticancer agents.
    Marks PA; Rifkind RA; Richon VM; Breslow R
    Clin Cancer Res; 2001 Apr; 7(4):759-60. PubMed ID: 11309319
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
    Weidle UH; Grossmann A
    Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
    Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
    Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylation of non-histone proteins modulates cellular signalling at multiple levels.
    Spange S; Wagner T; Heinzel T; Krämer OH
    Int J Biochem Cell Biol; 2009 Jan; 41(1):185-98. PubMed ID: 18804549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of a potent histone deacetylase inhibitor.
    Liu T; Kapustin G; Etzkorn FA
    J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Structure-activity relationships of histone deacetylase inhibitors].
    Tan YM; Huang WY; Yu NF
    Yao Xue Xue Bao; 2009 Oct; 44(10):1072-83. PubMed ID: 20055127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
    Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB
    Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
    Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
    Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases and cancer: causes and therapies.
    Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
    Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.